News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) On A Roll Even Before Breakthrough Hepatitis C Drug's Effects



2/5/2014 7:13:13 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Gilead Sciences announced financial gains for the fourth quarter and full year of 2013 on Tuesday, even though the Foster City company's latest blockbuster drug debuted just a month before the end of the year, signaling even more gains ahead.

Gilead announced fourth-quarter profits of $791.4 million, or 47 cents a share, on revenues of $3.12 billion, with net income gaining 3.8 percent and revenues jumping 21 percent from the same quarter a year ago. For the full year, Gilead posted gains from 2012 of 15 percent in revenues and 18.5 percent in profits to net income of $3.07 billion on revenues of $11.2 billion.

Help employers find you! Check out all the jobs and post your resume.

Read at Mercury News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES